Basic Information
ExeVir Bio is a Belgian company dedicated to developing therapies based on single-domain antibodies to help patients combat viral infections. The company is leveraging an antibody technology platform derived from llamas to generate potent antiviral treatments, providing broad protection against coronaviruses. They employ highly innovative and clinically validated VHH technology to develop treatments for viral infections that could pose significant global threats. ExeVir Bio has created a rapid response platform for antiviral drugs. Due to the short timeframe of its platform, it can quickly produce new drug candidates, enabling agile responses to emerging health threats. The resulting protein-based therapeutics are sufficiently stable and can be produced cost-effectively to allow for true global application.